BURNING ROCK BIOTECH LTD NasdaqGM:BNR Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS) based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various cancer types, including pan-cancer, lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, and ovarian cancer. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples, and OncoCompass, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore, which assesses microsatellite loci related to MSI status and detects mutations in genes associated with gastrointestinal cancers. It also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of the key products. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

Location: No. 5, Xingdao Ring Road North, Guangzhou, 510005, China | Website: https://www.brbiotech.com | Industry: Diagnostics & Research | Sector: Healthcare